Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Ribozyme targeting

Jonathan B Weitzman

Genome Biology 2002, 3:spotlight-20020321-01  doi:10.1186/gb-spotlight-20020321-01

The electronic version of this article is the complete one and can be found online at:


Published:21 March 2002

© 2002 BioMed Central Ltd

Research news

In the March 19 Proceedings of the National Academy of Sciences, Kashani-Sabet et al. describe the use of plasmid-based ribozymes as functional genomics tools to unravel complex phenotypes, such as cancer metastasis (Proc Natl Acad Sci USA 2002, 99:3878-3883). They reasoned that ribozyme-based gene targeting in mice might overcome experimental problems associated with transgenesis and lethal knockout phenotypes. They tested the use of systemic administration of cationic liposome:DNA complexes (CLDCs) to express hammerhead ribozymes in tumour-bearing mice; they targeted the p65 and p50 subunits of the NF-kappaB transcription factor using expression plasmids based on Epstein-Barr virus and including 35-bp ribozymes. They injected the CLDCs into the bloodstream of mice and noted a reduction in NF-κB proteins in metastatic tumour cells. The ribozymes affected the metastatic spread of melanoma cells; and the ribozymes appear to be more effective than antisense strategies, offering an experimental strategy to dissect complex traits in adult animals.

References

  1. [http://www.pnas.org] webcite

    Proceedings of the National Academy of Sciences

  2. Activators and target genes of Rel/NF-kB transcription factors.

    PubMed Abstract | Publisher Full Text OpenURL

  3. The experimental use of antisense oligonucleotides: a guide for the perplexed.

    PubMed Abstract | Publisher Full Text OpenURL